Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,247

Document Document Title
WO/2019/027456A1
The present disclosure generally pertains to novel water soluble oligomeric and polymeric additives derived from oligomeric and polymeric amines; esters or halides of twin tail alkyl group comprising acids with intervening quaternary amm...  
WO/2019/027855A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I) Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or d...  
WO/2019/027856A1
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or ...  
WO/2019/026994A1
The present invention provides a pharmaceutical composition for the treatment or prevention of cognitive function diseases or disorders, wherein the pharmaceutical composition contains a compound represented by formula (I), an enantiomer...  
WO/2019/016269A1
The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.  
WO/2019/011279A1
The present disclosure relates to an N-(substituted naphthyl-ethyl) substituted amide compound and uses thereof serving as a melatonin receptor agonist and 5-HT2c receptor antagonist, and specifically relates to the compound of formula (...  
WO/2019/011349A1
Disclosed are an FLZ crystal B form, a preparation method, and a composition and the use thereof, in particular the crystal B form of an FLZ compound (I) (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)- N-(4-h...  
WO/2019/008506A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defi...  
WO/2019/009317A1
Provided are: a novel compound usable as an organic tag which has a high stability under acidic conditions in peptide synthesis, etc.; and a method for highly efficiently producing a peptide wherein the compound is used as an organic tag.  
WO/2019/005841A1
Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial in...  
WO/2018/236913A1
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...  
WO/2018/237344A1
Disclosed herein are methods and compounds for treating a cancer is characterized with an elevated expression of thioredoxin reductase (TrxR) or an elevated expression of peroxiredoxin (PRDX). In some embodiments, also disclosed herein a...  
WO/2018/227620A1
Disclosed is a method for enantioselective synthesis of cis-imidazolines and related structures through chiral resolution. A chiral acid is used to separate enantiomeric precursors of the cis-imidazolines from a racemic mixture by select...  
WO/2018/225093A1
The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (IIIQ): wherein X6', a, b, C8', D8', L82', L83', R81', R82', R83', R84', R85', R86', z82'...  
WO/2018/226169A2
The present invention relates to a new diethanolamine derivative chelating agent having a high water solubility, a good chelating property, and biological degradation. The said new chelating agent can be prepared from reaction of diethan...  
WO/2018/220644A1
The invention provides lipo-polymeric nanoparticles and their preparation. The process involves dissolving polydiacetylene in dimethyl sulfoxide and a phospholipid in chloroform followed by adding 1-Ethyl-3-(3-dimethylaminopropyl) carbod...  
WO/2018/221604A1
The present invention provides a method for industrially producing: a pyrimidine compound having pest control efficacy; 2-[4-(trifluoromethyl)phenyl]ethylamine, which is a production intermediate of the pyrimidine compound; a phenylethyl...  
WO/2018/215070A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/215610A1
The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR...  
WO/2018/213140A1
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...  
WO/2018/210274A1
Provided is a novel, mild, highly effective, and economic process for co-producing formamide and monofunctional or polyfunctional acrylamide compounds.  
WO/2018/213082A1
Provided herein are compounds, compositions and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.  
WO/2018/212216A1
Provided is a method for producing an optically active isomer, the method including an asymmetry induction step in which an asymmetry-inducing agent is caused to act on chiral molecules having an enantiomeric-excess half-life period less...  
WO/2018/205299A1
Disclosed are a 4,5-disubstituted-1-hydro-pyrrole(2,3-f)quinolone-2,7,9-tric arboxylate compound, an analogue of same or a derivative of same, the structure thereof is as represented by formula I: where R1 and R4 respectively are indepen...  
WO/2018/205038A1
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...  
WO/2018/206239A1
A poly-lysine derivative obtained by a process comprising the steps of (a) heating an aqueous lysine solution to boiling (b) increasing temperature of the aqueous lysine solution to a reaction temperature in the range of about 105°C to ...  
WO/2018/208700A1
The present invention generally relates to targeted nanoparticle delivery to E-selectin- or P-selectin-positive cells or tissues. In particular, this invention discloses a method for preparing quinic acid-modified nanoparticles for targe...  
WO/2018/209290A1
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb oxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carb oxamide using selective crystallization with chir...  
WO/2018/206758A1
A polymeric stabilizing agent selected from poly-lysine derivatives obtained by the process comprising the steps of: I. heating an aqueous lysine solution to boiling II. increasing temperature of the aqueous lysine solution to a reaction...  
WO/2018/198523A1
The present invention provides a compound having excellent oil-gelling capability. More specifically, the present invention provides a compound represented by formula (1) , or a salt of the compound. [In the formula: R1 is a straight cha...  
WO/2018/196677A1
The present invention relates to a fluoroallylamine derivative and the use thereof. In particular, the present invention relates to a compound as shown in formula I, a prodrug, an isomer, an isotopically labelled compound, a solvate or a...  
WO/2018/196812A1
Disclosed are a boric acid and borate ester compound, and a preparation method and use therefor. Specifically disclosed are a borate ester compound of formula I, a crystal form, and pharmaceutically acceptable salts, hydrates or solvates...  
WO/2018/200931A1
The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cel...  
WO/2018/196860A1
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...  
WO/2018/200943A1
Compounds are provided having one of the the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein...  
WO/2018/195439A3
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.  
WO/2018/194157A1
The present invention addresses the problem of providing a compound which has high HTP, while having high temperature dependence of the HTP. The present invention also addresses the problem of providing a liquid crystal composition, a cu...  
WO/2018/195439A2
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.  
WO/2018/191789A1
The invention relates to compounds of Formula (I) and methods for their preparation. Also described are pharmaceutical compositions comprising a compound of Formula (I) and their use in the treatment or prevention of conditions associate...  
WO/2018/194908A1
A method for preparing photoactive perovskite materials. The method comprises the steps of: introducing a lead halide and a first solvent to a first vessel and contacting the lead halide with the first solvent to dissolve the lead halide...  
WO/2018/191719A1
A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid),...  
WO/2018/191657A1
Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, G1, G2 and n are as defined herein. Use of the compounds as a component of lip...  
WO/2018/184196A1
Provided are a method for preparing 2-arylmalonamide and applications of the method. The method uses 2-(cyclohexylene) malononitrile as raw material that undergoes an aromatization-hydrolysis reaction under the effects of an oxidizer and...  
WO/2018/177865A1
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...  
WO/2018/181986A1
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...  
WO/2018/183523A1
An enhanced pyrotechnic composition including an obscurant, a fuel, an oxidizer, and a nonivamide-cyclic anhydride adduct.  
WO/2018/177383A1
The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a...  
WO/2018/177488A1
Acrylamide photoinitiators are provided, in which a photoinitiator moiety and an acrylamide are incorporated into the photoinitiator structure.  
WO/2018/177151A1
Compounds such as vidofludimus and its analogues useful in modulating the activity of nuclear receptor FXR. Also disclosed are the methods for treating FXR-mediated disease or process in a mammal, comprising administering to the mammal a...  
WO/2018/176158A1
There are provided PVP-PLA block copolymers as defined in Formula (I): I wherein, x is an initiator alcohol having a boiling point greater than 145°C, n is, on average, from 20 and 40, and m is, on average, from 10 and 40, wherein the b...  

Matches 1 - 50 out of 20,247